<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283435</url>
  </required_header>
  <id_info>
    <org_study_id>PROTOCOL 500</org_study_id>
    <nct_id>NCT04283435</nct_id>
  </id_info>
  <brief_title>Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium</brief_title>
  <official_title>Effect of Sildenafil on Uterine and Endometrial Vasculature in Women With Thin Endometrium Having Frozen-Thawed IVF Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Management of Thin endometrium in IVF is challenging. Thin endometrium is often defined as &lt;7&#xD;
      mm or &lt; 8 mm on the day of Human Gonadotropin administration(Bu and Sun, 2015; Wu et al.,&#xD;
      2014).&#xD;
&#xD;
      Its incidence is 1-2.5% in most studies ( AlGhamdi et al.,2008).&#xD;
&#xD;
      Endometrial thickness and endometrial vascularity is closely linked to endometrial&#xD;
      receptivity.Improving endometrial receptivity is a predictor of the success in IVF.&#xD;
&#xD;
      Many medications have been tried to improve endometrial thickness as Aspirin,sildenafil&#xD;
      citrate,luteal estradiol and Granulocyte colony stimulating factor.&#xD;
&#xD;
      Nitric oxide (NO) is a key signaling molecule involved in the vasodilator response of smooth&#xD;
      muscle cells. NO activates the cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG)&#xD;
      pathway within smooth muscle cells to promote smooth muscle cell relaxation. Sildenafil&#xD;
      citrate inhibits phosphodiesterase 5 (PDE5) maintaining activation of cGMP and PKG and&#xD;
      maximizing the effect of existing NO, thus facilitating smooth muscle cell relaxation. The&#xD;
      potent vasodilator action of sildenafil has led researchers to evaluate sildenafil as a&#xD;
      treatment in assisted reproduction where low uterine blood flow is perceived to be a&#xD;
      contributor to implantation failure (Fairouzabadi et al.2013).&#xD;
&#xD;
      The investigators aim at this study to investigate the role of sildenafil citrate on&#xD;
      endometrial and subendometrial vasculature in women with thin endometrium undergoing&#xD;
      Frozen-Thawed IVF cycles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Randomised-controlled trial .The investigators recruited 100 women who are known to&#xD;
      have thin endometrium in previous IVF cycles (failed/cancelled cycles).&#xD;
&#xD;
      They are randomised into group A (50 women) : preparation of the endometrium with Estradiol&#xD;
      valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova,Payer,Germany) from the&#xD;
      first day of the cycle till 12th day and The investigators add placebo from the first day of&#xD;
      the cycle till the day of starting progesterone (It will be stopped 3 days before embryo&#xD;
      transfer).Group B (50 women): The investigators add Sildenafil citrate (Viagra,pfizer,United&#xD;
      states) to the estradiol valerate. Sildenafil 50 mg will be used daily from the first day of&#xD;
      the cycle till the day of starting progesterone (It will be stopped 3 days before embryo&#xD;
      transfer). The embryos will be transferred depending on their age on day 3 or day 5.&#xD;
&#xD;
      At the transfer date ,the investigators will assess the endometrial thickness, endometrial&#xD;
      volume, uterine artery doppler indices (RI,PI) as well as 3D endometrial vascular indices&#xD;
      (VI,FI,VFI) .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>One hundred envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Pregnancy rate</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>at the time of embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial volume</measure>
    <time_frame>at the time of embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine artery doppler indices</measure>
    <time_frame>at the time of embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3D endometrial and subendometrial vascular indices(VI,FI.VFI)</measure>
    <time_frame>at the time of embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>IVF</condition>
  <condition>Endometrial Receptivity</condition>
  <arm_group>
    <arm_group_label>estradiol valerate + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>preparation of the endometrium with Estradiol valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova) .from the first day of the cycle till 12th day and we add placebo from the first day of the cycle till the day of start progesterone (we stop 3 days before embryo transfer).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estradiol valerate + Sildenafil citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We add Sildenfil citrate 50 mg daily from the first day of the period till the day of starting the progesterone. and stop 3 days before the embryo transfer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)</description>
    <arm_group_label>estradiol valerate + Sildenafil citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)</description>
    <arm_group_label>estradiol valerate + placebo</arm_group_label>
    <other_name>Pregnacare vitamins (Vitabiotics,UK)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Valerate</intervention_name>
    <description>Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.</description>
    <arm_group_label>estradiol valerate + Sildenafil citrate</arm_group_label>
    <arm_group_label>estradiol valerate + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women (25 -40 years) undergoing IVF frozen-Thawed cycles and known to have good&#xD;
             quality embryos.&#xD;
&#xD;
          -  previous thin endometrium (&lt; 8mm on at least 3 previous cycles) with normal&#xD;
             Hysteroscopy findings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women less than 25 years old or more than 40 years old.&#xD;
&#xD;
          -  abnormal hysteroscopic findings.&#xD;
&#xD;
          -  women with congenital uterine anomalies.&#xD;
&#xD;
          -  History of previous uterine surgery&#xD;
&#xD;
          -  Any contraindication to Sildenafil as Previous history of cardiac disease or stroke.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females undergoing IVF</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eman Elkattan, MD</last_name>
    <phone>01212529213</phone>
    <email>emyelkattan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wafaa Ramadan, MD</last_name>
    <phone>01019944328</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Eman Elkattan</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

